<code id='C2ADEC2BEB'></code><style id='C2ADEC2BEB'></style>
    • <acronym id='C2ADEC2BEB'></acronym>
      <center id='C2ADEC2BEB'><center id='C2ADEC2BEB'><tfoot id='C2ADEC2BEB'></tfoot></center><abbr id='C2ADEC2BEB'><dir id='C2ADEC2BEB'><tfoot id='C2ADEC2BEB'></tfoot><noframes id='C2ADEC2BEB'>

    • <optgroup id='C2ADEC2BEB'><strike id='C2ADEC2BEB'><sup id='C2ADEC2BEB'></sup></strike><code id='C2ADEC2BEB'></code></optgroup>
        1. <b id='C2ADEC2BEB'><label id='C2ADEC2BEB'><select id='C2ADEC2BEB'><dt id='C2ADEC2BEB'><span id='C2ADEC2BEB'></span></dt></select></label></b><u id='C2ADEC2BEB'></u>
          <i id='C2ADEC2BEB'><strike id='C2ADEC2BEB'><tt id='C2ADEC2BEB'><pre id='C2ADEC2BEB'></pre></tt></strike></i>

          
          WSS
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion